Cargando…

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis

We report a rare case of advanced lung cancer with epidermal growth factor receptor and anaplastic lymphoma kinase co-alterations and brain metastasis, in which icotinib treatment was effective for both the primary lung tumor and the brain metastasis. The patient achieved important clinical remissio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Chenyang, Wang, Ji, Zheng, Shu, Chai, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087704/ https://www.ncbi.nlm.nih.gov/pubmed/27822065 http://dx.doi.org/10.2147/OTT.S121923

Ejemplares similares

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
por: Xu, Jianping, et al.
Publicado: (2016)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
Publicado: (2017)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib
por: Zhu, Zhouyu, et al.
Publicado: (2016)

Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients
por: Mannam, Sneha Sai, et al.
Publicado: (2023)

Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report
por: Wu, Ka, et al.
Publicado: (2019)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium
por: Anjali, V.R., et al.
Publicado: (2019)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
por: Bi, Rui, et al.
Publicado: (2019)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study
por: Jiang, Ai-Ying, et al.
Publicado: (2018)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases
por: Ying, Xiaofang, et al.
Publicado: (2020)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients
por: Zhou, Xueheng, et al.
Publicado: (2019)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
por: Liu, Yu-Tao, et al.
Publicado: (2020)

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
por: Zhang, Ping, et al.
Publicado: (2018)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report
por: Lu, Zhiqin, et al.
Publicado: (2021)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis
por: Qu, Jian, et al.
Publicado: (2017)

Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status
por: Han, Xiaoyu, et al.
Publicado: (2020)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0ule11754oiegubds7ts08bsuh